Bicara Therapeutics (NASDAQ:BCAX) Research Coverage Started at Cantor Fitzgerald

by · The Cerbat Gem

Cantor Fitzgerald assumed coverage on shares of Bicara Therapeutics (NASDAQ:BCAX – Free Report) in a research report sent to investors on Tuesday, Marketbeat Ratings reports. The brokerage issued an overweight rating on the stock. Cantor Fitzgerald also issued estimates for Bicara Therapeutics’ FY2024 earnings at ($1.61) EPS.

Several other research analysts also recently commented on the stock. Stifel Nicolaus began coverage on shares of Bicara Therapeutics in a research note on Tuesday. They issued a buy rating and a $47.00 target price on the stock. Morgan Stanley initiated coverage on shares of Bicara Therapeutics in a report on Tuesday. They issued an overweight rating and a $35.00 price target on the stock. Finally, TD Cowen started coverage on shares of Bicara Therapeutics in a research note on Tuesday. They set a buy rating for the company.

View Our Latest Analysis on BCAX

Bicara Therapeutics Stock Up 2.2 %

Shares of Bicara Therapeutics stock opened at $19.41 on Tuesday. Bicara Therapeutics has a one year low of $18.33 and a one year high of $27.94.

Insider Activity

In related news, Director Ra Capital Management, L.P. acquired 1,833,000 shares of Bicara Therapeutics stock in a transaction on Monday, September 16th. The shares were acquired at an average cost of $18.00 per share, with a total value of $32,994,000.00. Following the transaction, the director now owns 4,303,418 shares in the company, valued at $77,461,524. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, Director Ra Capital Management, L.P. acquired 1,833,000 shares of the stock in a transaction on Monday, September 16th. The stock was acquired at an average cost of $18.00 per share, for a total transaction of $32,994,000.00. Following the completion of the acquisition, the director now directly owns 4,303,418 shares of the company’s stock, valued at approximately $77,461,524. This represents a 0.00 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder James E. Flynn acquired 70,000 shares of the business’s stock in a transaction on Tuesday, September 17th. The shares were purchased at an average cost of $18.00 per share, for a total transaction of $1,260,000.00. Following the completion of the transaction, the insider now owns 897,587 shares in the company, valued at approximately $16,156,566. This represents a 0.00 % increase in their position. The disclosure for this purchase can be found here.

About Bicara Therapeutics

(Get Free Report)

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.

Read More